In their recently published article, Dr Aberegg and colleagues described interesting results of a literature search for randomized controlled trials comparing mortality of therapies for critically ill adults in fi ve high impact journals over a 10 year period [1] . Th e authors show that the predicted delta (the eff ect size of a therapy compared to control) used for power calculations was substantially larger than the observed delta in the majority of the included studies. Th ey conclude that this fi nding, referred to as 'delta infl ation' , led to underpowered trials in the fi eld of critical care medicine.
